True or false: methyl thioadenosine phosphorylase (MTAP) loss is a rare alteration? Healthcare providers, if you’re not seeing MTAP loss in ~1 in 10 solid tumors, you may be missing out on clinical trial opportunities. Explore our abstract for more: spkl.io/63324AU56K

Explore a new review article published in spkl.io/63328AWm9w – “Circulating tumor DNA as a biomarker in early phase clinical trials.” Read more: spkl.io/63320AWm9j

"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."

New #study at #GI26 utilizes genomic data from Foundation Medicine to explore the relationship between ERBB2 amplification and gene- and protein-level expression in GI cancers to understand combined predictive value.

Our team is excited to attend #GI26 and to join oncology leaders in discussing the latest innovations shaping gastrointestinal (GI) cancer care. #Research highlights we’re looking forward to sharing include four new abstracts on MTAP loss in GI cancers.

Connect with Foundation Medicine at #GI26! Learn more about the latest advancements in comprehensive genomic profiling at booth 8. Learn more & schedule a meeting: spkl.io/63320Amj1M

Join us for the session “2026: The new priorities in oncology R&D and diagnostics” featuring Foundation Medicine CEO, Dan Malarek at this year’s @endpts.com at #JPM26 event. Learn more: spkl.io/63321AlaTD

New #ProstateCancer research published in @CCR_AACR – “Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer”: spkl.io/63320Acu2w

#Research leveraged real-world data to evaluate changes in ctDNA tumor fraction & blood tumor mutational burden to assess treatment response to immune checkpoint inhibitors in a pan-tumor setting. Learn more: spkl.io/63328AcuwI

Innovations in precision medicine require collaboration, actionable insights and a commitment to advancing cutting-edge science. Explore how we are helping our #biopharma partners turn scientific promise into progress in our new blog: spkl.io/63329AcBID

#DYK that MTAP loss reporting can vary across NGS vendors? In a study from Sarah Cannon Research Institute, Foundation Medicine’s tissue NGS detected MTAP loss in about 1 out of 10 solid tumors. It’s not a rare biomarker – even though it can be hard to identify accurately.

Our team is excited to present two new pieces of research in #breastcancer that show the importance of robust homozygous gene loss reporting in BRCA1/2 and PTEN. Learn more from Foundation Medicine at #SABCS25 - booth 1342: spkl.io/63323A9iEF

New #research in non-small cell lung cancer reflects a simulated, retrospective analysis of oncology biomarker assays. Read this publication in The Oncologist –spkl.io/63322A9Vdk

Join us at #SABCS25, December 9-12. Visit booth 1342 to learn how Foundation Medicine’s comprehensive genomic testing portfolio can help inform treatment options for advanced breast cancer patients. Learn more: spkl.io/63325AgY6S

Join us at booth B111, hall 4 at #ESMOAsia25 for our final booth talks, including sessions around Foundation Medicine’s tissue-based RNA sequencing test, our clonal hematopoiesis algorithm and use cases around AI and precision medicine. Find out more: spkl.io/63320Agvl6

Our #BoothTalks series are underway at #ESMOAsia25! Learn more about Saturday’s sessions below. Click here for more information: spkl.io/63320AgmGr

Announcement ‼️ – 100 approved companion diagnostic indications! Through this historic milestone, we are proud to reaffirm our commitment to transforming lives in cancer and beyond and continuing to help drive a new wave of precision medicine: spkl.io/63322AglR0

Attending #ESMOAsia25? Join us tomorrow as we kick off our “Booth Talks” – booth B111, hall 4. Learn about Friday's programming below. Want to connect with our team? Find the full Booth Talks schedule and more information here: spkl.io/63323AgkSS

New publication – learn more about new research published in @plosone.org: “Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples.” Click here: spkl.io/63327AgprD

Connect with Foundation Medicine at #ASH25! Interested in exploring how comprehensive genomic profiling can impact your work in #hematology? Visit booth 1816 or schedule a meeting with us to learn more about our hematologic profiling capabilities: spkl.io/63324AeLKA

Join us for an industry satellite symposium at #ESMOAsia25 “From Insights to Outcomes: How Comprehensive Genomic Profiling Redefines Cancer Care.” Learn more below! Connect with our team at this year’s meeting: spkl.io/63329AeIrU#ESMOAsia25

At #ESMOAsia25, Foundation Medicine is excited to join industry peers from across the Asia-Pacific region to discuss the latest research & innovations happening in oncology. Visit Foundation Medicine at booth B111, hall 4 to meet with our team. Learn more: spkl.io/63327AeniJ

#NewResearch – “Intratumoral heterogeneity and immunotherapy resistance: clinical implications” Read more: spkl.io/63320AencI

A recently published investigator-initiated study utilized Foundation Medicine’s tissue- and blood-based comprehensive genomic profiling to identify actionable alterations: “Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial” in @natmed.nature.com

We are proud to support @lungevity.bsky.social's Cancer Precision Medicine Commons to further raise awareness and education around biomarker testing this #CancerBiomarkerDay. Click here for more information and resources: spkl.io/63321Abxmz

Our latest webinar with @precmedonline.bsky.social will focus on the evolving landscape of biomarker-genomic treatment for advanced non-small cell #lungcancer (NSCLC). Join us for this expert-led conversation – register today: spkl.io/63320AwAb2

#NewResearch published in Cancer Research Communications: “Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcoma.” Click to learn more: spkl.io/63327AwdBx

Foundation Medicine will be at #AMPath25 at booth 320! Schedule time to explore solutions that help deliver deeper #genomic insights and more actionable results: spkl.io/63321AwwxT

Honoring #LungCancer Awareness Month this November and all those within our community and beyond who have been impacted by the disease. Follow us this month for patient stories, resources and more.

We’re proud to collaborate with Manifold, the AI data platform for life sciences, to bring enhanced analytics capabilities to our FoundationInsights® platform. Learn more: www.foundationmedicine.com/press-releas...

Join us at #ISLB25 – November 1-3. Meet our team at booth 201 to learn more about how Foundation Medicine and our FDA-approved #LiquidBiopsy test provides information that can help physicians determine treatment paths for their patients with advanced cancer.

Hear from experts through a series of webinars on the importance of biomarker testing, specifically comprehensive genomic profiling, in #BreastCancer treatment and care. Explore our “Pioneers in Practice – Breast Series” at the link here: spkl.io/63323AXq8Z

#NewResearch publication in @natgenet.nature.com – “Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.” Learn more: spkl.io/63324AXoYY

#NewResearch being presented at #ESMO25 features data utilizing Foundation Medicine’s tissue-based RNA sequencing test in #BreastCancer. Visit us at booth 3028 in Hall 3.2! Discover more and connect with our team at this year’s meeting: spkl.io/63321AXB0f

#ESMO25 research - data leveraged the research use version of Foundation Medicine's tissue-free treatment response monitoring assay: “Circulating tumor DNA dynamics correlate with response to carboplatin with or without nivolumab in metastatic TNBC" spkl.io/63329AXBLl#ESMO25

Explore the latest in research involving Foundation Medicine’s homologous recombination deficiency signature (HRDsig) across key disease areas, including ovarian, lung & gastric cancers. Attending #ESMO25? Visit our team - booth 3028, Hall 3.2. Learn more: spkl.io/63328AXBag

#NewResearch being presented as an oral presentation at #ESMO25 includes a new study aimed at characterizing the demographic and genomic differences between patients with MET+ and MET- papillary renal cell carcinoma. Visit us at booth 3028 in hall 3.2: spkl.io/63323An0Cl

Our team is excited to attend #Targets25 in Boston next week! Visit booth 216 to learn more about Foundation Medicine’s high-quality portfolio of precision diagnostic solutions. Scroll through for more about our research being presented. Connect with us: spkl.io/63328AnIH4

Foundation Medicine is excited to join the oncology community at #ESMO25! Click to learn more about the research being presented: spkl.io/63324Anb7e

Visit booth 3028 in Hall 3.2 at #ESMO25 for discussions around the latest advancements in cancer care. Join us for our #BoothTalk series and connect with Foundation Medicine experts on our latest innovations in precision diagnostics: spkl.io/63322ApiAy

Join Foundation Medicine and Precision Medicine Online for an expert presentation on how comprehensive genomic profiling can help provide insights to inform treatment decisions in HR+ HER2- advanced breast cancer. Register for the webinar today: spkl.io/63325Apif9

#NewPublication in Cancer Research Communications: “Clinical validity of FoundationOne®Liquid CDx for detection of BRAF V600E in colorectal cancer.”: spkl.io/63328ApiFs *FDA-approved; Rx only; doesn't guarantee treatment match or that all alterations will be found spkl.io/63329ApiFt#NewPublication

Foundation Medicine will be at #ESMO25! Visit us at booth 3028, located in Hall 3.2 to meet with our team. Learn more about our activities at this year’s meeting and schedule a time with us: spkl.io/63322ApSyg

Foundation Medicine is committed to advancing access to high-quality biomarker tests to deliver on the value of precision medicine. We are proud to award our 2025 IDEA Program grant to My Style Matters, Inc. & H.Y.P.E. to Empower, Inc. Learn more: spkl.io/63323ApbPD

Proud to recognize #BreastCancerAwarenessMonth this October and to help support greater education and information around the disease.

Foundation Medicine is proud to support the National Organization for Rare Disorders’ (@nordrare.bsky.social) Rare Cancer Coalition this #RareCancerDay. Let’s raise awareness and stand with the rare cancer community. Learn more: spkl.io/63320ATd3E#RareCancerDay

Our Knowledge Center provides educational and informational resources on the latest in precision oncology. Check out our latest content, including a blog and podcast on “Unlocking the Future of Breast Cancer Treatment.” Click here to explore more: spkl.io/63325ATdOR

Connect with Foundation Medicine at Biomarkers & Precision Medicine in London! Schedule a meeting to explore the latest biomarker-driven innovations: spkl.io/63324AT1OM

High-quality research helps shapes our understanding of cancer and advances precision medicine for all. Our #NewResearch demonstrates the role Foundation Medicine’s tests & proprietary biomarkers play in transforming approaches to cancer care. #WorldCancerResearchDay

Excited to share the launch of our new tissue-informed whole genome sequencing molecular residual disease (Tissue-informed #WGS #MRD)test for research use in early to late-stage cancers through our FlexOMx™ Lab. Read more: spkl.io/63323ArxYJ